The Ink4a-Arf-Ink4b locus has a crucial role in both cellular senescence and tumorigenesis. JmjC domain-containing histone demethylase 1b (Jhdm1b, also known as Kdm2b and Fbxl10), the mammalian paralog of the histone demethylase Jhdm1a (also known as Kdm2a and Fbxl11), has been implicated in cell-cycle regulation and tumorigenesis. In this report, we show that Jhdm1b is a histone H3 lysine 36 (H3K36) demethylase. Knockdown of Jhdm1b in primary mouse embryonic fibroblasts inhibits cell proliferation and induces cellular senescence in a pRb-and p53 pathway-dependent manner. Notably, the effect of Jhdm1b on cell proliferation and cellular senescence is mediated through derepression of p15 Ink4b , as loss of p15 Ink4b function rescues cell-proliferation defects in Jhdm1b-knockdown cells. Chromatin immunoprecipitation on ectopically expressed Jhdm1b demonstrates that Jhdm1b targets the p15 Ink4b locus and regulates its expression in an enzymatic activity-dependent manner. Alteration of Jhdm1b level affects Ras-induced neoplastic transformation. Collectively, our results indicate that Jhdm1b is an H3K36 demethylase that regulates cell proliferation and senescence through p15 Ink4b .
The Ink4a-Arf-Ink4b locus encodes three crucial cell-cycle inhibitors, including p16 Ink4a , p15 Ink4b and Arf (known as p14 in humans and p19 in mice). The two members of the Ink4 protein family inhibit the binding of D-type cyclins to cyclin-dependent kinase 4 and 6 (Cdk4/6), inhibiting the phosphorylation of retinoblastoma (Rb) family proteins and preventing G1-S phase transition in cells. The Arf protein, which shares two common p16 Ink4a exons but contains a distinct open reading frame, is able to activate the p53 pathway through sequestration of the p53 negative regulator Mdm2 (reviewed in refs. 1, 2) .
The Ink4a-Arf-Ink4b locus has a crucial role in determining cellular response to oncogenic signals. In normal cells, inappropriate oncogenic stimulation activates this locus and leads to cellular senescence. However, dysregulation of this locus can facilitate tumorigenesis through several oncogenic signaling pathways. The importance of this locus in cellular defense against tumorigenesis is further supported by evidence that Ink4a-Arf-Ink4b is frequently deleted or mutated in various human primary tumors [3] [4] [5] [6] . In addition, combined deletion of Ink4a-Arf with Ink4b in mice results in a broader spectrum of tumors compared to those found in mice with individual genetic deletions, indicating that genes in this locus work synergistically to prevent tumor development and that p15 Ink4b is a critical tumor suppressor in the absence of p16 Ink4a (ref. 7) . Because this locus controls both cellular senescence and tumorigenesis, tight regulation is crucial under physiological conditions. Although many oncoproteins and Polycomb group proteins have been shown to regulate Ink4a-Arf expression 8, 9 , the mechanism that controls p15 Ink4b expression remains unclear.
Jhdm1b is a paralog of the first identified histone lysine demethylase, Jhdm1a, which targets H3K36 for demethylation 10 . This fact, as well as their high level of homology within the catalytic JmjC domain (79%), led us to predict that the demethylase activity against the H3K36 methyl group is conserved between both paralogs ( Supplementary Fig. 1 online) . However, in a recent report, Jhdm1b was implicated in the demethylation of trimethylated histone H3 lysine 4 (H3K4me3) in vivo 11 . In addition, the reported biological functions of this protein are also controversial. Although two groups have identified Jhdm1b as a hotspot for proviral insertion in murine tumors generated by random MMLV mutagenesis, the locus has paradoxically been identified as both an oncogene and a tumor suppressor, depending on the screen and functional studies used 12, 13 . In addition, subsequent studies have reported that Jhdm1b is a negative regulator of c-Jun 14 or ribosomal RNA (rRNA) genes 11 , further implicating Jhdm1b in tumor suppression.
In an effort to resolve these apparent discrepancies, we set out to use methods well established in our previous studies to characterize the biochemical properties and biological function of Jhdm1b using primary mouse embryonic fibroblast (MEF) cells, which maintain normal cellcycle regulatory pathways, to study protein function. We report here that Jhdm1b is an H3K36-specific histone demethylase that functions to promote cellular proliferation and inhibit cellular senescence through the silencing of the p15 Ink4b tumor-suppressor gene.
RESULTS

Jhdm1b is an H3K36me2-specific demethylase
In an effort to explain the difference between activity predictions based on domain homology and reported in vivo substrate specificity 11 , we first investigated the in vitro and in vivo catalytic activity of Jhdm1b. To this end, recombinant protein was flag-affinity purified from baculovirus-infected Sf 9 cells ( Supplementary Fig. 2a online) and subjected to a histone-demethylase assay by measuring radioactive formaldehyde release 10 . Of all the substrates tested, only the H3K36-specific SET2-labeled histone substrate could be demethylated by Jhdm1b, indicating that, as predicted, Jhdm1b has a similar substrate specificity to Jhdm1a 10 (Fig. 1a) .
Because Jhdm1b was implicated in the demethylation of H3K4me3 in vivo 11 , we tested its capacity to demethylate H3K4me3 in vitro. To this end, we purified a new batch of wild-type Jhdm1b along with a mutant Jhdm1b-H211A that is predicted to disrupt the protein's enzymatic activity ( Supplementary Fig. 2b ). As controls, we also purified the H3K36me2-specific demethylase, Jhdm1a 10 , and the H3K4me3-specific demethylase, Rbp2 (ref. 15) . Incubation of these proteins with SET2-labeled histone substrate confirmed efficient formaldehyde release for Jhdm1a and Jhdm1b but not the mutant Jhdm1b-H211A (Fig. 1b) . In addition, Jhdm1b showed about onethird the activity of Jhdm1a when equivalent amounts of proteins were assayed. Furthermore, incubation of these proteins with substrate labeled by a mutated form of the SET7, SET7-Y245A, which generates H3K4me2 and H3K4me3 (ref. 16 ), did not show efficient release of formaldehyde above background levels. However, incubation of Rbp2 with the same substrate resulted in formaldehyde release (Fig. 1b) , demonstrating that Jhdm1b has no H3K4me3-demethylase activity under the assay conditions.
To further define the substrate specificity of Jhdm1b, we incubated the protein with core histones purified from HeLa cells and analyzed the product by western blotting using methylation state-specific antibodies. These experiments showed that Jhdm1b, like its paralog, Jhdm1a, can specifically demethylate H3K36me2 and H3K36me1 histone substrates (Fig. 1c) . However, it does not alter H3K4-methylation levels (Fig. 1c) .
To characterize the substrate specificity of Jhdm1b in vivo, we used HEK293 cells selected for adherence (AD293) and overexpressed Jhdm1b and Jhdm1b-H211A via retroviral infection. Quantitative reverse-transcriptase PCR (qRT-PCR) verified that there were similar levels of stable expression of wild-type and mutant Jhdm1b (Fig. 1d) . Western blot analysis demonstrated that overexpression of wild-type, but not mutant, Jhdm1b resulted in a marked decrease in H3K36me2 levels ( Fig. 1e) . Although we observed a small decrease in H3K36me3, as well as H3K4me3, this minor decrease did not rely on a functional JmjC domain, as it could also be seen in the cells overexpressing the catalytic mutant. Given that overexpression of Jhdm1b in HeLa cells was previously reported to result in decreased H3K4me3 levels 11 , we overexpressed Jhdm1b in HeLa cells by lentiviral infection. Western blot analysis of the histones purified from the infected HeLa cells confirmed our observation in the HEK293 cells ( Supplementary  Fig. 3a online) . Taken together, our results indicate that Jhdm1b is an H3K36-specific, rather than H3K4-specific, demethylase.
Jhdm1b knockdown affects cell proliferation and senescence
We next explored the function of Jhdm1b in primary cells. Given that previous analyses of Jhdm1b tumor-suppressor function had been carried out in transformed or immortalized cell lines, we postulated that the paradoxical conclusions about the role of Jhdm1b in cancer might be due to the many genetic alterations necessary for the establishment of these cell lines. We therefore designed a short hairpin RNA (shRNA) that can target all three murine isoforms of Jhdm1b and introduced it into primary MEFs by lentiviral infection (Jhdm1b KD). After selection, the knockdown efficiency (90%) was verified by qRT-PCR (Fig. 2a) . Notably, stable knockdown of Jhdm1b resulted in a substantial decrease in cell proliferation (Fig. 2b) , a phenotype reminiscent of that seen in MEF cells with reduced levels of the Polycomb group protein Ring1b 17, 18 . On the basis of this observation, a shRNA directed against Ring1b was introduced into MEF cells (Ring1b KD), and knockdown efficiency was determined by qRT-PCR to be 90% (Fig. 2a) . Furthermore, knockdown of Jhdm1b had no substantial effect on Ring1b levels and vice versa (Fig. 2a) .
Comparison of the cell-proliferation levels of Ring1b KD, Jhdm1b KD and control cells confirmed Ring1b's strong effects on cell proliferation and indicated that Jhdm1b knockdown, although drastic, did not achieve the same level of cell-growth inhibition as achieved by the Ring1b knockdown (Fig. 2b) . Bromodeoxyuridine (BrdU) pulse labeling followed by flow-cytometry analysis revealed that Jhdm1b KD resulted in a two-fold reduction in the number of cells in S phase as compared to control MEFs, whereas a four-fold reduction was observed in the Ring1b KD cells (Fig. 2c) . In addition, Ring1b has been shown to have an important role in regulating cellular senescence as a component of the Polycomb-repressive complex 1 (PRC1), which enacts negative regulation of the p16 Ink4a locus 17, 19 . To investigate whether Jhdm1b KD also contributes to premature cellular senescence, Ring1b and Jhdm1b KD MEFs were analyzed for the presence of ( S E T 2 )
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Anti-K4me2 senescence-associated b-galactosidase (SA-b-galactosidase) at different passages. Although only a few cells stained positive for SAb-galactosidase in control MEFs at passage 5, Jhdm1b KD MEFs underwent cellular senescence at a markedly increased rate ( Fig. 2d ), whereas Ring1b knockdown had the most drastic ability to induce senescence. Taken together, these results suggest that Jhdm1b is involved in the positive regulation of the cell cycle and the negative regulation of passage-dependent cellular senescence.
Jhdm1b regulates cell proliferation through p15 Ink4b
Cellular proliferation and senescence is tightly regulated through the p53 and pRb pathways, and both of these cellular pathways can be inhibited by the introduction of SV40 T antigen into primary cells 20 .
To determine whether the function of Jhdm1b in cell proliferation and senescence is pRb and p53 dependent, we inactivated both pathways by retroviral expression of the SV40 large T antigen in MEFs and then subjected the cells to Jhdm1b knockdown. Knockdown of Jhdm1b does not alter the cellular proliferation of MEF cells when the p53 and pRb pathways are blocked by the SV40 large T antigen ( Supplementary Fig. 4a online). Consistent with this result, the percentage of S-phase cells, as indicated by BrdU incorporation, is not altered by Jhdm1b knockdown under these conditions ( Supplementary Fig. 4b ). In addition, Jhdm1b knockdown-induced cellular senescence, as assessed by the appearance of SA-b-galactosidase staining, was also blocked in SV40 large T antigen-transduced cells ( Supplementary Fig. 4c ). Collectively, these data suggest that Jhdm1b's pro-growth and antisenescence properties act upstream of these two pathways. Previous studies have identified several genes whose expression is linked to Rb-regulated cellular senescence and p53-dependent apoptosis 21 . These genes include members of the Ink4a-Arf-Ink4b tumorsuppressor locus, p18 (also known as Ink4c) and the cell-cycle regulators p27 (also known as Cdkn1b) and p21. To determine whether loss of Jhdm1b function affected expression of any of these genes, we performed qRT-PCR in control, Jhdm1b KD and Ring1b KD cells. Jhdm1b KD resulted in a marked upregulation of p15 Ink4b (Fig. 3a) . In agreement with the crucial role of Ring1b in the PRC1 complex, Ring1b knockdown resulted in substantial upregulation of p16 Ink4a (refs. 17,19) . In addition, we also observed a marked increase in p15 Ink4b mRNA levels. The effect of Jhdm1b and Ring1b knockdown on p15 Ink4b and p16 Ink4a levels was also confirmed by western blotting (Fig. 3b) . These data are consistent with the observation that the p16 Ink4a protein has a more potent inhibitory effect on cell proliferation, as well as the notion that p15 Ink4b functions to back up the function of p16 Ink4a (ref. 7) . Notably, similarly to what was observed for Ring1b knockdown, the expression of p21, a p53-pathway target gene, was not altered by Jhdm1b knowckdown (Fig. 3a) . To analyze whether p15 Ink4b is a key mediator of Jhdm1b's function in cellular proliferation, we derived primary MEFs from p15 Ink4b -null mice 22 and performed knockdown of Jhdm1b or Ring1b. Loss of p15 Ink4b function could largely rescue the slow proliferation and low BrdU incorporation caused by Jhdm1b knockdown (Fig. 3c,d) . Thus, we conclude that Jhdm1b regulates cellular proliferation and senescence by negatively regulating the expression of the p15 Ink4b tumor-suppressor gene in primary cells.
Jhdm1b regulates p15 Ink4b expression through H3K36 demethylation H3K36 methylation, which has been linked to active gene transcription in organisms from yeast to humans, is present within the coding regions of genes being actively transcribed and tends to peak toward the 3¢ end of transcribed regions [23] [24] [25] [26] . The mechanism by which high levels of H3K36me2 are excluded from the promoters of active genes, as well as the functional significance of this observation, is still not clear for higher eukaryotes. However, it has been demonstrated that SET2 association with elongating RNA polymerase II is at least partly responsible for this phenomenon in yeast 25 . To investigate whether the demethylase activity of Jhdm1b directly contributes to p15 Ink4b regulation and cellular proliferation, we attempted to rescue the Jhdm1b KD MEFs with small interefering RNA (siRNA)-resistant wild-type Flag-Jhdm1b as well as catalytically deficient mutant, Flag-Jhdm1b-H211A. After confirming equal expression of the rescue constructs ( Supplementary Fig. 5 online) , we analyzed their effects on cellular proliferation. Re-introduction of wild-type Jhdm1b rescued the growth defects, whereas re-introduction of the catalytically defective mutant did not (Fig. 4a) . In addition, re-introduction of wild-type Jhdm1b, but not the mutant, restored p15 Ink4b expression to control levels (Fig. 4b) . Thus, both normal cell proliferation and p15 Ink4b repression depends on the demethylase activity of Jhdm1b. Having established that transcriptional repression of p15 Ink4b depends on the H3K36-demethylase activity of Jhdm1b, we used chromatin immunoprecipitation (ChIP) assays to decipher whether p15 Ink4b is a direct target of Jhdm1b. Because none of the available Jhdm1b antibodies worked for immunoprecipitation in our hands, we resolved to retrovirally express Flag-Jhdm1b in primary MEF cells and performed ChIP assays using Flag antibodies. Flag-Jhdm1b was found to be specifically enriched three-fold above background in regions just upstream (amplicon 1) and surrounding the transcription start site (amplicon 2) of p15 Ink4b when compared with mock-infected cells (Fig. 4c,d) . However, the protein was not enriched within the p15 Ink4b intron (amplicon 3; Fig. 4c,d ). ChIP analysis of H3K36me2 levels at these same regions in Jhdm1b KD and control cells revealed that knockdown of Jhdm1b resulted in an increase in the H3K36me2 levels across the locus when compared to control cells (Fig. 4e) , suggesting that Jhdm1b might also have an active role in the demethylation of H3K36me2 downstream of the transcription start site. However, it has not escaped our attention that increased transcription of the gene may itself contribute to increases in H3K36me2 within the coding region. Furthermore, rescue of the knockdown by wild-type Jhdm1b resulted in H3K36me2 levels below those of control cells (Fig. 4e) . In addition, H3K36me2 levels within the Gapdh locus were unchanged for all samples (data not shown). Taken together, these data suggest that p15 Ink4b is a direct Jhdm1b target and that Jhdm1b regulates p15 Ink4b expression through active demethylation of H3K36.
Jhdm1b cooperates with Ras to induce oncogenic transformation
All of the data presented above indicate that Jhdm1b functions as a proto-oncogene through its ability to repress transcription of the p15 Ink4b locus. In an effort to further establish the oncogenic potential of Jhdm1b, we assessed the contribution of the protein to colony formation using knockdown or overexpression in p53-null MEFs, followed by superinfection of retroviral H-Ras12V virus. Results of soft-agar colony formation analysis indicate that coexpression of Ras and Jhdm1b in p53-null MEF cells results in an increase in Ras-induced oncogenic transformation (Fig. 5a) . Conversely, knockdown of Jhdm1b inhibited Ras-induced colony formation (Fig. 5b) . Together, these data support the notion that Jhdm1b acts as a proto-oncogene in primary MEFs.
DISCUSSION
In this report, we show that Jhdm1b, like its paralog Jhdm1a, functions as an H3K36 demethylase in vitro and in vivo. Recombinant Jhdm1b purified from baculovirus-infected Sf9 cells demethylates H3K36me2 in vitro in a radioactive formaldehyde-release assay and in histone western blot analysis (Fig. 1) . Furthermore, western blotting and ChIP analysis indicate that overexpression of Jhdm1b results in global H3K36me2 demethylation (Fig. 1e) and gene-specific H3K36me2 demethylation (Fig. 4) in different cell types, including HeLa and HEK293 cells (Supplementary Fig. 3a) . In addition, the previously suggested nucleolar-staining pattern of Jhdm1b could not be observed in either HeLa cells 11 ( Supplementary Fig. 3b ) or AD293 cells (Supplementary Fig. 5b) .
In addition to the substrate specificity of Jhdm1b, its role in tumorigenesis has also been a point of contention. One of the earliest reports of Jhdm1b function came out of a genetic screen for tumorsuppressor genes in mouse lymphomas 13 . The authors identified several biallelic retroviral insertion events at the Jhdm1b locus when several of the induced lymphomas were analyzed. However, further analysis of additional tumor samples revealed locus insertion that left the Jhdm1b coding region intact. This leaves open the possibility that the tumor-manifesting retroviral insertions could either activate or suppress Jhdm1b function. Therefore, the potential of Jhdm1b to serve as an oncogene or a tumor suppressor was not resolved in this study.
In addition, some indirect evidence suggested that Jhdm1b may act as a tumor suppressor, including a link to the negative regulation of c-Jun 14 and a description of its role in the negative regulation of rRNA genes 11 . However, these experiments were carried out in various cell lines in which crucial pathways important for cellular senescence and tumorigenesis (such as those regulated by the Ink4a-Arf-Ink4b locus) are also disrupted. Thus, further evidence would be required to support the relevance of previously identified gene targets in a normal context. A recent report that screened 44 random MMLV-induced T-cell lymphomas identified the Jhdm1b locus as an insertion hotspot 12 . This study revealed multiple, orientated provirus insertions upstream of the canonical Jhdm1b promoter and further implicated a role for Jhdm1b overexpression in the immortalization of primary MEF cells. In this study, we provide several lines of evidence that support the idea that Jhdm1b may indeed be a proto-oncogene. First, we demonstrate in primary MEFs that knockdown of Jhdm1b resulted in cell-proliferation defects and increased senescence (Fig. 2) . Furthermore, we demonstrate that Jhdm1b contributes to the regulation of cell proliferation and senescence by directly repressing the expression of the p15 Ink4b tumor suppressor (Figs. 3 and 4) . Notably, p15 Ink4b seems to be an important target that mediates Jhdm1b function in cellular proliferation because loss of p15 Ink4b function can largely rescue the Jhdm1b knockdown effects (Fig. 4) . Finally, Jhdm1b can cooperate with Ras to transform primary MEF cells (Fig. 5) . Therefore, we conclude that Jhdm1b is indeed a proto-oncogene that functions at least partially by controlling the expression of the p15 Ink4b tumor suppressor through removal of H3K36me2.
METHODS
Cloning and cell-line generation. All of the cell lines used in this study were maintained in DMEM supplemented with 10% (v/v) FBS and 1% (v/v) penicillin/ streptomycin. Primary MEFs harvested from day 13.5 C57BL/6 and p15 Ink4b -null mouse embryos were plated into a P75 flask. The confluent cells were frozen down and considered passage 1. The cells were split at 1:5 for each passage. Cell growth was measured by plating 5 Â 10 5 MEFs on a 100-mm plate in triplicate for each group. The cell number was counted using a hemocytometer at the time points indicated. Selection and stable maintenance of exogenous plasmids was accomplished in the presence of either 1 mg ml -1 (AD293 cells) or 4 mg ml -1 (MEF cells) puromycin. PCR amplification of an EST clone corresponding to full-length Jhdm1B (NM_001003953) was cloned into a modified pFastBacHT B vector (Invitrogen) containing an N-terminal Flag-epitope tag for baculovirus generation, as per the manufacturer's protocol (Invitrogen). Full-length Jhdm1B was subcloned into the pMSCVpuro vector (Clontech) for stable cell-line generation using the manufacturer's protocol. A lentiviral system was used for the HeLa expression experiment, as it generated higher viral titers and increase infection efficiency to more than 90% (as determined by flag staining). The Jhdm1b-H211A mutant was generated using overlapping PCR and subcloning. Stable knockdown was achieved using a lentiviral system obtained from the US National Institutes of Health (NIH) AIDS Research and Reference Reagent Program. The mouse U6 promoter was cloned from mouse genomic DNA and inserted into the NotI site of pTY-EF1a-nLacZ. For the LV-U6 shRNA-Pgk-Pac construct, the Pgk-Pac cassette at NotI/EcoRI sites replaced the EF1a-nLacZ cassette. The hairpin RNAs targeting Jhdm1b (5¢-GCTCCAACTCAGTTACTGT-3¢), Ring1b (5¢-GCAGTACACCATTTA CATA-3¢) and control (5¢-GTTCAGATGTGCGGCGAGT-3¢) were cloned into BBSI/HindIII sites under the U6 promoter 27 . To generate wild-type and mutant Jhdm1b-H211A rescue constructs, the siRNA target site of Jhdm1b was mutated to 5¢-ATTGCAGTTGAGTTACTGT-3¢ by PCR mutagenesis. The siRNA-resistant wildtype and mutant Jhdm1b cDNAs were PCR amplified and cloned into either the SpeI/EcoRI site of the LV vector or the NotI/XbaI of the RV vector.
In vitro histone demethylase formaldehyde-release assay. Histone substrates were radiolabeled and formaldehyde-release assays were performed as previously described 10, 28 . Unless otherwise stated, 5 mg of Flag-purified recombinant protein was incubated in the presence of labeled substrate corresponding to 60,000 input counts and demethylase buffer (50 mM HEPES-KOH, pH 8.0, 70 mM Fe(NH4) 2 (SO4) 2 , 1 mM a-ketoglutarate and 2 mM ascorbate) for 1 h at 37 1C. Released, labeled formaldehyde was extracted using a modified NASH technique and subjected to scintillation counting. Data are presented as counts per minute in the extracted sample.
Western blot analysis and immunostaining. Total protein was extracted by RIPA buffer. Purified native histones from HeLa cells or acid-extracted histones from the indicated cell lines were prepared as previously described 29 . Antibodies against specific methylation states were used at dilutions ranging from 1 in 250 to 1 in 1,000: H3K36me1 ( BrdU incorporation and cycle cycle analysis. MEFs were grown in the presence of 10 mM BrdU for 60 min. The cells were harvested and fixed overnight using 75% (v/v) ethanol. Fixed cells were stained with FITC-conjugated mouse anti-BrdU antibody (BD biosciences, 347583) and propidium iodide. The stained cells were analyzed by flow cytometry (BD FACSCalibur) and data was analyzed using WinMDI version 2.9 (TSRI Flowcytometry Software).
Senescence associated-b-galactosidase assay. Cells were washed twice with PBS and immersed in fixation buffer (2% (w/v) formaldehyde, 0.2% (w/v) glutaraldehyde in PBS) for 10 min. After two additional PBS washes, the cells were allowed to stain overnight in staining solution (40 mM citric acid/sodium phosphate, pH 6.0, 150 mM NaCl, 2.0 mM MgCl 2 , 1 mg ml -1 X-gal).
Reverse-transcription quatitative polymerase chain reaction. RNA was extracted and purified from cell lines using Qiashredder (Qiagen) and RNeasy (Qiagen) spin columns, was treated with DNase (Promega RQ1 Dnase) and cleaned up using an Qiagen RNeasy column (Qiagen). RNA (1 mg) was subjected to reverse transcription using random primers (Promega) and the Improm-II reverse transcription kit (Promega). cDNA levels were assayed via real-time PCR using SYBR GreenER (Invitrogen) and analyzed on an ABI 7300 Real Time PCR System with SDS software version 1.3.1. qRT-PCR primer sequences are available in Supplementary Table 1 online.
ChIP assay. ChIP assays using Flag antibody were carried out as previously reported 30 with the following modifications: 20 ml of M2 agarose (Sigma) was used in the immunoprecipitation and chromatin-bound beads were washed three times each in TSEI (0.1% (w/v) SDS, 1% (v/v) Triton-X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris, pH 8. Soft agar colony assay. p53-null MEFs were transduced with different LVs. 48 h after transduction, the cells were superinfected with retroviral H-Ras12V virus. We mixed 5,000 cells with 0.35% (w/v) top agar and plated onto 0.5% (w/v) basal agar. At 14 d after plating, the cells were stained with 0.005% (w/v) crystal violet and the colony number was counted.
Standard error reporting. All in vitro formaldehyde-release assays and cellbased assays were performed in triplicate, and error bars represent the s. 
